Indoco Remedies clinical research organisation AnaCipher gets UK MHRA accreditation

Published On 2021-08-28 06:00 GMT | Update On 2021-08-28 13:22 GMT

Mumbai: Indoco Remedies Ltd. has recently announced the receipt of GCP & GLP accreditation from the UK-MHRA (Medicines and Healthcare Products Regulatory Agency) for its Clinical Research Organisation - AnaCipher, located at Hyderabad for the virtual inspection carried out from 4th – 7th May and 10th - 11th May, 2021.

The inspection covered all the phases of Bioequivalence studies and was conducted successfully.

"This is an exciting step in our journey of excellence and a validation of our adherence to delivering quality services to our customers worldwide.", stated Ms. Aditi Kare Panandikar, Managing Director, Indoco Remedies Limited.

AnaCipher CRO, based in Hyderabad, is a USFDA inspected clinical research facility and is spread over 30,000 sq. ft area with 98 beds and staffed by experienced professionals providing clinical trial solutions and conducts Bioequivalence and Bioavailability (BA/BE) studies at its facility. The CRO has successfully completed more than 500 studies in multiple therapeutic areas such as, cardiovascular, diabetes, oncology, anti-retrovirals and antacids.

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma company with presence in 55 countries

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritional, Cardiovascular, Anti-Diabetics, Pain Management, etc. Top Indoco brands include Cyclopam, Febrex Plus, SensodentK, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM, Methycal, etc.

Read also: Indoco Remedies bags tenders worth Rs 140 crore for Allopurinol Tablets in Germany

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Indoco Remedies clinical research organisation AnaCipher gets UK MHRA accreditation

Similar News

Mankind Pharma wins CDSCO nod to start Phase 1 trials of Autoimmune drug candidate

India seeks to boost drug exports to semi regulated markets in Africa, Latin America, Southeast Asia

Jubilant Ingrevia appoints Sonia Dharap as Vice President - Sales, Business Development (US)

EMA warns of sharp rise in illegal medicines sold in EU

Indegene opens new center in Pune, boosts India presence

Indian medical devices share increased from 10% to 30% of domestic requirements in last 5 years: DoP Secretary

AstraZeneca announces Rs 176 crore investments in India to expand Chennai GITC

Eli Lilly gets USFDA Breakthrough Therapy designation for olomorasib with Keytruda for lung cancer